全文获取类型
收费全文 | 55060篇 |
免费 | 3540篇 |
国内免费 | 786篇 |
专业分类
耳鼻咽喉 | 373篇 |
儿科学 | 1012篇 |
妇产科学 | 672篇 |
基础医学 | 2487篇 |
口腔科学 | 872篇 |
临床医学 | 6426篇 |
内科学 | 5278篇 |
皮肤病学 | 718篇 |
神经病学 | 2617篇 |
特种医学 | 949篇 |
外科学 | 3716篇 |
综合类 | 12200篇 |
一般理论 | 2篇 |
预防医学 | 5123篇 |
眼科学 | 314篇 |
药学 | 9144篇 |
161篇 | |
中国医学 | 4947篇 |
肿瘤学 | 2375篇 |
出版年
2024年 | 164篇 |
2023年 | 941篇 |
2022年 | 1912篇 |
2021年 | 2504篇 |
2020年 | 2487篇 |
2019年 | 2055篇 |
2018年 | 1905篇 |
2017年 | 2079篇 |
2016年 | 2411篇 |
2015年 | 2342篇 |
2014年 | 6159篇 |
2013年 | 5407篇 |
2012年 | 5010篇 |
2011年 | 4702篇 |
2010年 | 3461篇 |
2009年 | 2438篇 |
2008年 | 2170篇 |
2007年 | 1987篇 |
2006年 | 1597篇 |
2005年 | 1145篇 |
2004年 | 879篇 |
2003年 | 727篇 |
2002年 | 558篇 |
2001年 | 473篇 |
2000年 | 429篇 |
1999年 | 313篇 |
1998年 | 255篇 |
1997年 | 209篇 |
1996年 | 161篇 |
1995年 | 149篇 |
1994年 | 142篇 |
1993年 | 109篇 |
1992年 | 70篇 |
1991年 | 70篇 |
1990年 | 64篇 |
1989年 | 74篇 |
1988年 | 54篇 |
1987年 | 61篇 |
1986年 | 60篇 |
1985年 | 152篇 |
1984年 | 228篇 |
1983年 | 195篇 |
1982年 | 209篇 |
1981年 | 180篇 |
1980年 | 148篇 |
1979年 | 147篇 |
1978年 | 101篇 |
1977年 | 65篇 |
1976年 | 74篇 |
1975年 | 67篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
目的:探讨保妇康凝胶联合诺氟沙星治疗宫颈糜烂的临床效果。方法将100例宫颈糜烂患者根据随机数字表法分为观察组和对照组各50例。观察组给予保妇康凝胶和诺氟沙星联合治疗,对照组单独给予治糜灵栓治疗,比较两组患者临床症状的变化,并对临床疗效进行评价。结果观察组治愈率为86.00%,明显高于对照组的74.00%,临床症状评分改善较对照组明显,且其临床症状消失的时间短于对照组,差异均有统计学意义(P<0.05)。结论保妇康凝胶与诺氟沙星合用比治糜灵栓治疗宫颈糜烂效果更佳,且治愈时间上明显较优,值得临床上推广应用。 相似文献
3.
目的:探讨微波配合序贯扩肛治疗陈旧性肛裂的临床疗效。方法:选取陈旧性肛裂患者78例,随机分为对照组和治疗组,每组各39例。对照组患者采用后卫内括约肌部分切断治疗,治疗组患者采用微波配合序贯扩肛治疗。结果:观察组患者术中出血量、切口愈合时间均少于对照组(P<0.05),并发症发生率低于对照组(P<0.05)。结论:采用微波配合序贯扩肛治疗陈旧性肛裂,临床疗效显著。 相似文献
4.
5.
目的:分析糖尿病视网膜病变合并黄斑水肿联合采用激光与复方血栓通胶囊治疗的临床疗效。方法:选取我院2017年1月—2019年1月收治的200例糖尿病视网膜病变合并黄斑水肿患者为研究对象,随机分为两组。对照组单独行激光治疗,观察组于对照组基础上联合复方血栓通胶囊治疗,对比两组临床疗效、治疗前后IL-6(白介素-6)、VEGF(血管内皮生长因子)、NOS(血清一氧化氮合成酶)水平变化情况。结果:对照组总有效率(68.00%,68/100)较观察组总有效率(98.00%,98/100)更高(P<0.05);与对照组对比,观察组治疗后NOS水平更高,IL-6、VEGF水平更低(P<0.05)。结论:糖尿病视网膜病变合并黄斑水肿联合采用激光与复方血栓通胶囊治疗的临床疗效显著,值得推广。 相似文献
6.
7.
《Vaccine》2016,34(45):5436-5441
Influenza is a viral infection that affects much of the global population each year. Vaccination remains the most effective tool for preventing the disease. Live attenuated influenza vaccine (LAIV) has been used since the 1950s to protect humans against seasonal influenza. LAIVs developed by the Institute of Experimental Medicine (IEM), Saint Petersburg, Russia, have been successfully used in Russia since 1987.In 2006, the World Health Organization (WHO) announced a Global action plan for influenza vaccines (GAP). WHO, recognizing potential advantages of LAIV over the inactivated influenza vaccine in a pandemic situation, included LAIV in the GAP.BioDiem Ltd., a vaccine development company based in Melbourne, Australia which held the rights for the Russian LAIV, licensed this technology to WHO in 2009. WHO was permitted to grant sub-licenses to vaccine manufacturers in newly industrialized and developing countries to use the Russian LAIV for the development, manufacture, use and sale of pandemic and seasonal LAIVs. To date, WHO has granted sub-licenses to vaccine manufacturers in China (Changchun BCHT Biotechnology Co., Ltd.), India (Serum Institute of India Pvt. Ltd.) and Thailand (Government Pharmaceutical Organization). In parallel, in 2009, IEM signed an agreement with WHO, under which IEM committed to supply pandemic and seasonal candidate vaccine viruses to the sub-licensees.This paper describes the progress made by collaborators from China, India, Russia and Thailand in developing preventive measures, including LAIV against pandemic influenza. 相似文献
8.
目的:探讨小儿化脓性脑膜炎的临床疗效和临床观察。方法回顾分析76例小儿化脓性脑膜炎患者的临床资料。结果76例患儿中,54例患儿治愈,16例患儿好转,6例患儿转科治疗。治疗前患儿脑脊液检查外观混浊的检出率和球蛋白阳性的检出率分别为73.7%和92.1%,显著高于治疗后的外观混浊的检出率7.9%和球蛋白阳性的检出率5.3%,治疗前后对比差异具有统计学意义(P<0.05)。结论对接诊的疑似化脓性脑膜炎的患儿及早地诊断、治疗,可以有效减少患儿并发症及后遗症的发生,提高患儿的治愈率。 相似文献
9.
10.
BackgroundHealth research reporting guidelines for case reports (CARE - CAse REport) published in 2013 and 2017 have become a generally accepted standard for publishing case reports. The CARE guidelines represent an architectural framework for writing an evidence-based case report that can be customized as need for a specialty (or disease) if needed. We aim to develop a CARE guideline extension for acupuncture following the EQUATOR Network (Enhancing the QUAlity and Transparency Of health Research) and the 2010″Guidance for Developers of Health Research Reporting". We have established a group of international experts including; clinicians, researchers and methodologists. We performed a needs assessment based on a review of acupuncture case reports published in the indexed medical literature. The needs assessment will be followed by (1) a series of expert interviews to establish a draft, (2) a modified Delphi process, and (3) a consensus meeting. Following the consensus meeting we will pilot test the CARE draft before publishing the CARE extension for acupuncture.MethodsWe will develop the CARE extensions for acupuncture following recommendations of the EQUATOR Network and the 2010 "Guidance for Developers of Health Research Reporting". We will establish an international multidisciplinary group including clinical practitioners, acupuncturists, researchers of reporting guidelines on acupuncture, clinical epidemiologists and statisticians.We performed a needs assessment, reviewing published case reports using acupuncture as a therapeutic intervention from indexed medical journals (PubMed-PMC and Medline, Scopus, Embase, the Allied and Complementary Medicine Database (AMED), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Wan Fang database, Chinese BioMedicine database (CBM), China National Knowledge Infrastructure (CNKI), and VIP). In consultations with advisors we will develop a draft of potential items to be included in the CARE extension for acupuncture. Then we will conduct a modified Delphi process of at least three rounds, hold a face-to-face consensus meeting, pilot test and submit the CARE extension for acupuncture for publication.ConclusionThe development of a widely accepted CARE extension for acupuncture for case reports published in indexed medical journals. These guidelines will follow the EQUATOR Network recommendations and the 2010 "Guidance for Developers of Health Research Reporting". 相似文献